ArticleCellular and molecular neurobiology2026
Genetic Prioritization of Plasma Proteins Across Dementia Subtypes: A Proteome-Wide Mendelian Randomization and Bayesian Colocalization Analysis.
Article in Cellular and molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Dementia is clinically and biologically heterogeneous, and genetically supported plasma protein associations across dementia subtypes remain incompletely characterized. We aimed to genetically prioritize plasma proteins associated with overall dementia and major dementia subtypes using proteome-wide Mendelian randomization (MR) and Bayesian colocalization. We used the UK Biobank Pharma Proteomics Project (UKB-PPP) as a harmonized source of cis-protein quantitative trait loci (cis-pQTLs) for 2,941 Olink-measured plasma analytes. The European-ancestry discovery cis-pQTL analysis included up to 34,557 participants, whereas 54,219 participants were profiled in the overall UKB-PPP. Outcomes included FinnGen R10 genome-wide association studies (GWAS) for dementia, Alzheimer's dementia, vascular dementia, frontotemporal dementia, and unspecified dementia, plus a European GWAS for dementia with Lewy bodies. At the nominal threshold of P < 0.05, 134, 132, 102, 78, 101, and 112 exploratory protein-outcome signals were observed for dementia, Alzheimer's dementia, vascular dementia, frontotemporal dementia, dementia with Lewy bodies, and unspecified dementia, respectively; 23 associations remained significant after outcome-specific Benjamini-Hochberg false discovery rate (FDR) correction. Key FDR-significant proteins included APOE, NECTIN2, PVR, SERPINF2, GRN, TREM2, and ATXN2L. The strongest risk and protective associations were NECTIN2 with Alzheimer's dementia (odds ratio [OR] = 2.650, 95% confidence interval [CI]: 1.875-3.744, FDR-adjusted P = 1.58 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.